Thiazide Explained

Thiazide
Imageclass:skin-invert-image
Use:hypertension, edema
Atc Prefix:C03A
Biological Target:sodium-chloride symporter

Thiazides are a class of diuretics based on the chemical structure of benzothiadiazine. Thiazides are used in the treatment of hypertension. The first approved drug of this class was chlorothiazide in 1958.

Thiazide-like diuretics, such as indapamide, are sometimes called thiazides because they act on the same receptor, but do not have the thiazide chemical structure. The thiazide receptor is a sodium-chloride transporter that pulls NaCl from the lumen in the distal convoluted tubule of the kidneys. Thiazide diuretics inhibit this receptor, causing the body to release NaCl and water into the urine, thereby increasing the amount of urine produced each day.

Medical uses

Thiazide diuretics are primarily used to treat the hypertension (high blood pressure) and edema (swelling) caused by water overload as well as certain conditions related to unbalanced calcium metabolism.

Water balance

Hypertension

Thiazides and thiazide-like diuretics are generally recommended amongst other classes as first-line treatment for hypertension (high blood pressure).[1] [2] [3] They have been in use since their introduction in 1958.[4] Low-dose thiazides are more effective at treating hypertension than beta blockers and are similar to ACE inhibitors. Low-dose thiazides are tolerated as well as the other classes of medications for hypertension including ACE inhibitors, beta blockers and calcium channel blockers.[5] In general, the thiazides and thiazide-like diuretics used in hypertension reduce the risk of death, stroke, heart attack and heart failure.[5]

Drug TypeGeneric drug nameThreshold betweenlow dose and high dose

(mg/day)

Thiazide diureticChlorothiazide500
Hydrochlorothiazide50
Bendroflumethiazide5
Methyclothiazide5
Trichlormethiazide2
Thiazide-like diureticChlorthalidone50
Indapamide5

Diabetes insipidus

Thiazides can be used to paradoxically decrease urine flow in people with nephrogenic diabetes insipidus.[6] Thiazides may also be useful in treating hyponatremia (low blood sodium) in infants with central diabetes insipidus.[7]

Calcium balance

Urinary stones

Thiazides are useful in treating kidney stones and bladder stones that result from hypercalciuria (high urine calcium levels). Thiazides increase the uptake of calcium in the distal tubules, to moderately reduce urinary calcium. Thiazides combined with potassium citrate, increased water intake and decreased dietary oxalate and sodium can slow or even reverse the formation of calcium-containing kidney stones.[8] High-dose therapy with the thiazide-like diuretic indapamide can be used to treat idiopathic hypercalcinuria (high urine calcium with unknown cause).[9]

Osteoporosis

Hypocalcemia (low blood calcium) can be caused by a variety of conditions that reduce dietary calcium absorption, increase calcium excretion or both. Positive calcium balance occurs when calcium excretion is decreased and intake remains constant so that calcium is retained within the body.[10] Higher levels of retained calcium are associated with increased bone mineral density and fewer fractures in individuals with osteoporosis.[10] By a poorly understood mechanism, thiazides directly stimulate osteoblast differentiation and bone mineral formation, further slowing the course of osteoporosis.[11]

Dent's disease

Thiazides may be used to treat the symptoms of Dent's disease, an X-linked genetic condition that results in electrolyte imbalance with repeated episodes of kidney stones. A case study of two brothers with the condition, two years of treatment with hydrochlorothiazide reduced the incidence of kidney stones and improved kidney function.[12] The thiazide-like diuretic chlortalidone reduced urine calcium oxalate in seven of the eight males with inactivated CLCN5 gene that participated in the study.[13] Inactivation of the CLCN5 gene causes Dent's disease type 1.[14] The rare nature of Dent's disease makes it difficult to coordinate large controlled studies, so most evidence for thiazide use is with too few patients to make broad recommendations possible.[14]

Other uses

Bromine intoxication can be treated by giving intravenous saline with either thiazides or loop diuretics.[15]

Contraindications

Contraindications include:

Thiazides reduce the clearance of uric acid since they compete for the same transporter, and therefore raise the levels of uric acid in the blood. Hence, they are prescribed with caution in patients with gout or hyperuricemia.[16] [17]

Chronic administration of thiazides is associated with the increase of insulin resistance which can lead to hyperglycemia.[18]

Thiazides can decrease placental perfusion and adversely affect the fetus, so should be avoided in pregnancy.[17] [19]

Adverse effects

Mechanism of action

Thiazide diuretics control hypertension in part by inhibiting reabsorption of sodium (Na+) and chloride (Cl−) ions from the distal convoluted tubules in the kidneys by blocking the thiazide-sensitive Na+-Cl− symporter.[21] The term "thiazide" is also often used for drugs with a similar action that do not have the thiazide chemical structure, such as chlorthalidone, metolazone and indapamide. These agents are more properly termed thiazide-like diuretic.[22]

The membrane-associated phospholipase NAPE-PLD (N-acyl phosphatidylethanolamine-specific phospholipase D) of the endocannabinoid system is a renal and extrarenal target of "thiazide-type" (e.g., hydrochlorothiazide) and "thiazide-like" diuretics (e.g., chlorthalidone and indapamide). NAPE-PLD accounts for both their acute (diuresis and accompanying decrease of plasma volume) and chronic (reduction of arterial pressure through vascular dilation) therapeutic effects.[23]

Thiazide diuretics also increase calcium reabsorption at the distal tubule. By lowering the sodium concentration in the tubule epithelial cells, thiazides indirectly increase the activity of the basolateral Na+/Ca2+ antiporter to maintain intracellular Na+ level, facilitating Ca2+ to leave the epithelial cells into the renal interstitium. Thus, intracellular Ca2+ concentration is decreased, which allows more Ca2+ from the lumen of the tubules to enter epithelial cells via apical Ca2+-selective channels (TRPV5). In other words, less Ca2+ in the cell increases the driving force for reabsorption from the lumen.[24]

Thiazides are also thought to increase the reabsorption of Ca2+ by a mechanism involving the reabsorption of sodium and calcium in the proximal tubule in response to sodium depletion. Some of this response is due to augmentation of the action of parathyroid hormone.[25]

Chemistry

Thiazides are organic molecules with bi-cyclic structures that contain adjacent sulfur and nitrogen atoms on one ring. The molecule class thiazides are based on the chemical structure of benzothiadiazine.

Confusion sometimes occurs because thiazide-like diuretics such as indapamide are referred to as thiazides despite not having the thiazide chemical structure. When used this way, "thiazide" refers to a drug which acts at the thiazide receptor. The thiazide receptor is a sodium-chloride transporter that pulls NaCl from the lumen in the distal convoluted tubule of the kidneys. Thiazide diuretics inhibit this receptor, causing the body to release NaCl and water into the urine, thereby increasing the amount of urine produced each day. An example of a molecule that is chemically a thiazide but not used as a diuretic is methylchloroisothiazolinone, often found as an antimicrobial in cosmetics.[26]

Breastfeeding

Thiazides pass into breast milk and can decrease the flow of breast milk.[27] Thiazides have been associated with significant side effects in some nursing infants and should be administered to nursing mothers with caution.[28]

History

The thiazide diuretics were developed by scientists Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello of Merck and Co. in the 1950s,[29] and led to the marketing of the first drug of this class, chlorothiazide, under the trade name Diuril in 1958.[30] The research leading to the discovery of chlorothiazide was recognized by a special Public Health Award from the Lasker Foundation in 1975.[31]

Notes and References

  1. Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al.. 16 September 2025. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 152. 11. e114–e218. 10.1161/CIR.0000000000001356. free. 40811497.
  2. McEvoy . John William . McCarthy . Cian P . Bruno . Rosa Maria . Brouwers . Sofie . Canavan . Michelle D . Ceconi . Claudio . Christodorescu . Ruxandra Maria . Daskalopoulou . Stella S . Ferro . Charles J . Gerdts . Eva . Hanssen . Henner . Harris . Julie . Lauder . Lucas . McManus . Richard J . Molloy . Gerard J . 5 . 2024-08-30 . 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO) . European Heart Journal . 45 . 38 . 3912–4018 . en . 10.1093/eurheartj/ehae178 . 39210715 . free . 0195-668X.
  3. Mancia . Giuseppe . Kreutz . Reinhold . Brunström . Mattias . Burnier . Michel . Grassi . Guido . Januszewicz . Andrzej . Muiesan . Maria Lorenza . Tsioufis . Konstantinos . Agabiti-Rosei . Enrico . Algharably . Engi Abd Elhady . Azizi . Michel . Benetos . Athanase . Borghi . Claudio . Hitij . Jana Brguljan . Cifkova . Renata . 5 . 2023-12-01 . 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) . Journal of Hypertension . 41 . 12 . 1874–2071 . 10.1097/HJH.0000000000003480 . 1473-5598 . 37345492. free . 11379/603005 . free .
  4. Moser M, Feig PU. November 2009. Fifty years of thiazide diuretic therapy for hypertension. Archives of Internal Medicine. JAMA. 169. 20. 1851–6. 10.1001/archinternmed.2009.342. 19901136. free.
  5. Musini. Vijaya M. Gill. Rupam. Wright. James M. 2018-04-18. First-line drugs for hypertension. The Cochrane Database of Systematic Reviews. 2018. 4. CD001841. 10.1002/14651858.CD001841.pub3. 1469-493X. 6513559. 29667175.
  6. Magaldi. Antonio J.. 2000-12-01. New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrology Dialysis Transplantation. 15. 12. 1903–1905. 10.1093/ndt/15.12.1903. 11096127. 0931-0509. free.
  7. Welch. Thomas R.. 2015-09-01. Diuretics for diabetes insipidus. The Journal of Pediatrics. en. 167. 3. 503–505. 10.1016/j.jpeds.2015.07.029. 0022-3476. free.
  8. Web site: THIAZIDE DIURETICS FOR STONE PREVENTION Kidney Stone Evaluation And Treatment Program. kidneystones.uchicago.edu. 2019-07-22.
  9. Martins. M. C.. Meyers. A. M.. Whalley. N. A.. Margolius. L. P.. Buys. M. E.. 1996. Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. British Journal of Urology. 78. 2. 176–180. 10.1046/j.1464-410X.1996.00633.x. 8813907. 1464-410X.
  10. Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD005185. DOI: 10.1002/14651858.CD005185.pub2.
  11. Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi D. September 2007. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. Journal of the American Society of Nephrology. 18. 9. 2509–16. 10.1681/ASN.2007030348. 2216427. 17656470.
  12. Velasco. Nestor. Jayawardene. Satishkumar A.. Burgess. Helen K.. 2001-07-01. Dent's disease: can we slow its progression?. Nephrology Dialysis Transplantation. 16. 7. 1512–1513. 10.1093/ndt/16.7.1512. 11427657. 0931-0509. free.
  13. Scheinman. Steven J.. Asplin. John. Ploutz-Snyder. Robert J.. Why. Scott Van. Goodyer. Paul. Blowey. Douglas. D'Mello. Richard G.. Schurman. Scott. Raja. Khalid A.. 2002-12-01. Responsiveness of Hypercalciuria to Thiazide in Dent's Disease. Journal of the American Society of Nephrology. 13. 12. 2938–2944. 10.1097/01.ASN.0000036869.82685.F6. 1046-6673. 12444212. free.
  14. Web site: Dent Disease. NORD (National Organization for Rare Disorders). 2019-07-22.
  15. Trump. D. L.. Hochberg. M. C.. April 1976. Bromide intoxication. The Johns Hopkins Medical Journal. 138. 4. 119–123. 0021-7263. 131871.
  16. Web site: Medication Update.
  17. Web site: Hydrochlorothiazide, HCTZ (Microzide) Contraindications and Precautions . 2010-05-14 . https://web.archive.org/web/20101009210901/http://rx-s.net/weblog/more/hydrochlorothiazide_hctz_microzide_contraindications_and_precautions/ . 2010-10-09 .
  18. Rehman. Abdur. Setter. Stephen M.. Vue. Mays H.. 2011-11-01. Drug-Induced Glucose Alterations Part 2: Drug-Induced Hyperglycemia. Diabetes Spectrum. 24. 4. 234–238. 10.2337/diaspect.24.4.234. 1040-9165. free. subscription.
  19. Web site: Hypertension in Pregnancy - Gynecology and Obstetrics.
  20. Book: Dowd. Frank J. Johnson. Bart. Mariotti. Angelo. Pharmacology and Therapeutics for Dentistry - E-Book. 3 September 2016. Elsevier Health Sciences. 978-0-323-44595-5. 324–326. 4 November 2017.
  21. Duarte JD, Cooper-DeHoff RM . Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics . Expert Rev Cardiovasc Ther . 8 . 6 . 793–802 . June 2010 . 20528637 . 2904515 . 10.1586/erc.10.27 .
  22. Taler SJ . Initial Treatment of Hypertension. . N Engl J Med . 387 . 636–644 . 2018 . 7 . 29443671 . 2904515 . 10.1056/NEJMcp1613481 .
  23. Chiarugi S, Margheriti F, De Lorenzi V, Martino E, Garau G . NAPE-PLD is target of thiazide diuretics . Cell Chem Biol . 2025 . 32 . 3 . 449–462 . 39999832 . 10.1016/j.chembiol.2025.01.008 .
  24. Book: Longo, Dan L. Harrison's Principals of Internal Medicine, Vol. 2. 2012. McGraw-Hill. New York. 978-0-07-174887-2. 2285. etal.
  25. Book: Longo, Dan L. Harrison's Principals of Internal Medicine, Vol. 2. 2012. McGraw-Hill. New York. 978-0-07-174887-2. 3109. etal.
  26. 1992-01-01. 6 Final Report on the Safety Assessment of Methylisothiazolinone and Methylchloroisothiazolinone. Journal of the American College of Toxicology. 11. 1. 75–128. 10.3109/10915819209141993. 208506926. 0730-0913. free.
  27. Book: Gerald G. Briggs. Roger K. Freeman. Sumner J. Yaffe. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 2011. Lippincott Williams & Wilkins. 978-1-60831-708-0. 257–.
  28. Transfer of drugs and other chemicals into human milk . Pediatrics . 108 . 3 . 776–89 . September 2001 . 11533352 . 10.1542/peds.108.3.776. American Academy of Pediatrics Committee on Drugs . free .
  29. Beyer KH. 1993. Chlorothiazide. How the thiazides evolved as antihypertensive therapy. Hypertension. 22. 3. 388–91. 10.1161/01.hyp.22.3.388. 8349332. free.
  30. Web site: Drugs@FDA: FDA Approved Drug Products . https://web.archive.org/web/20071213104224/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails . December 13, 2007 .
  31. Web site: The Lasker Foundation - Awards .